$1,318.00
This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Patient subtypes
7 Symptoms
7 Risk factors
7 Diagnosis
9 TREATMENT
9 Iron supplements
9 Blood transfusion
9 Erythropoietin-stimulating agents (ESAs)
11 EPIDEMIOLOGY
13 MARKETED DRUGS
16 PIPELINE DRUGS
20 RECENT EVENTS AND ANALYST OPINION
20 Roxadustat for CIA (December 9, 2019)
22 KEY UPCOMING EVENTS
23 PROBABILITY OF SUCCESS
24 REVENUE OPPORTUNITY
25 CLINICAL TRIAL LANDSCAPE
26 Sponsors by status
27 Sponsors by phase
29 BIBLIOGRAPHY
29 Prescription information
31 APPENDIX
LIST OF FIGURES
16 Figure 1: Overview of pipeline drugs for CIA in the US
16 Figure 2: Pipeline drugs for CIA, by company
16 Figure 3: Pipeline drugs for CIA, by drug type
17 Figure 4: Pipeline drugs for CIA, by classification
21 Figure 5: Roxadustat for CIA (December 9, 2019): Phase III – MDS (US)
22 Figure 6: Key upcoming events in CIA
23 Figure 7: Probability of success in the marrow or peripheral blood stimulator pipeline
25 Figure 8: Clinical trials in CIA
25 Figure 9: Top 10 drugs for clinical trials in CIA
26 Figure 10: Top 10 companies for clinical trials in CIA
27 Figure 11: CIA trials status
28 Figure 12: CIA trials sponsors, by phase
LIST OF TABLES
11 Table 1: Chemotherapy-treated patients with CIA, by grade, in the US
14 Table 2: Marketed drugs for CIA
18 Table 3: Pipeline drugs for CIA in the US
20 Table 4: Roxadustat for CIA (December 9, 2019)
24 Table 5: Historical global sales, by drug ($m), 2015–19
24 Table 6: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!